SecBot SecBot

MNKD

MANNKIND CORP
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000899460 Biotech & Drug Discovery
$3.96 −0.17 (−4.12%)
Nov 16 4:00 PM ET · prev $4.13
Market cap
$1.3B
Small cap
Consensus
Buy
87% Buy or better · 15 analysts
Median target
$8.00
+102% · range $5.00–13.00
1 year
−20.5%
from $4.98 · Nov 17
30 days
+28.2%
from $3.09
52-week range
$2.28–6.21
−36% from high · low Mar 25
Avg volume 20D
3.29M
shares / day
Short interest
26.22M
≈8.2% of shares · +2.9%
Days to cover
10.3
at average volume
Insider net
−$791.3K
0 buyers · 2 sellers · since May 11
New fund stakes
0
Q3 2026 13F · 1 exit
Filing reports
12
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 1 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $791.3K.

  • InstitutionsBEARISH

    Q3 2026: 19 added (0 new), 33 trimmed or exited.

  • AnalystsBULLISH

    13 of 15 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +2.9% to 26.22M shares. 10.3 days to cover, ≈8.2% of shares.

  • TrendUPTREND

    11% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 6.

Who's buying

13F· Q3 2026
0
new positions
1
exit
FundMoveSharesValue
VOYA INVESTMENT MANAGEMENT LLCDOUBLED737,655$2.9M
Jump Financial, LLCDOUBLED496,320$1.9M
ALPS ADVISORS INCADD426,020$1.7M
BARCLAYS PLCADD341,143$1.3M
Rafferty Asset Management, LLCADD311,058$1.2M
Mariner, LLCTRIM303,873$1.2M
BNP PARIBAS FINANCIAL MARKETSADD297,940$1.2M
VANGUARD ASSET MANAGEMENT, LtdADD227,651$887.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 87% rate it Buy or better
Strong Buy4Buy9Hold2Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +102%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Nov 6, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight
Oct 20, 2026Cantor Fitzgerald
REITERATE
REITERATEOverweight
Oct 19, 2026Chardan Capital
INITIATE
INITIATEBuy
Oct 7, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Sep 11, 2026Cantor Fitzgerald
REITERATE
REITERATEOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$791.3K
sold · 2 insiders
DateInsiderTypeValue
Sep 25, 2026
Binder Steven B.
Director
Sep 25, 2026
SELL$128.5K
Sep 10, 2026
Binder Steven B.
Director
Sep 10, 2026
SELL$127.9K
Aug 7, 2026
Binder Steven B.
Director
Aug 7, 2026
SELL$158.5K
Jul 17, 2026
Binder Steven B.
Director
Jul 17, 2026
SELL$213.1K
Jul 17, 2026
Thomson David
EVP Genl Counsel & Secretary
Jul 17, 2026
SELL$97.6K
Jul 15, 2026
Binder Steven B.
Director
Jul 15, 2026
EXERCISE93,790 sh
Jul 15, 2026
Binder Steven B.
Director
Jul 15, 2026
TAX W/H$64.2K
Jul 15, 2026
Binder Steven B.
Director
Jul 15, 2026
TAX W/H$16.7K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.02-$0.02–-$0.02+0.0%$128.6M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

3 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
26,220,516
shares short
+2.9%
vs prior settlement
10.3
days to cover
≈8.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
State Street Corp filed a Schedule 13G disclosing a 4.7% passive stake in MannKind Corp as of September 30, 2026…
SC 13G · Impact 3/10
Nov 10, 2026 Other
MannKind to Participate in Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation
Nov 5, 2026 SEC
MannKind reported Q3 2026 total revenue of $101.9M (+24% YoY), driven by Furoscix ($22.4M, up from zero) and royalties…
8-K · Impact 5/10
Nov 5, 2026 SEC
MannKind reported Q3 2026 total revenue of $101.9M (+24% YoY), slightly below the $108.5M consensus, and GAAP EPS of…
PRESS-RELEASE · Impact 5/10
Sep 30, 2026 Inst.
VOYA INVESTMENT MANAGEMENT LLC · DOUBLED
737,655 shares ($2.9M)
Sep 30, 2026 Inst.
Jump Financial, LLC · DOUBLED
496,320 shares ($1.9M)
Sep 25, 2026 Insider
Binder Steven B. sold 39,051 shares
Director @ $3.29 ($128.5K)
Sep 10, 2026 Insider
Binder Steven B. sold 33,558 shares
Director @ $3.81 ($127.9K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

12 filings · 5 press releases · 3 bullish · 2 bearish · 1 mixed · 6 neutral
All MNKD filing & press-release reports (17)